Plerixafor
Plerixafor is a bicyclam CXCR4 chemokine receptor antagonist that blocks the interaction between CXCR4 and its ligand CXCL12/SDF-1, thereby mobilizing hematopoietic stem and progenitor cells from the bone marrow into the peripheral blood. It is used in combination with granulocyte colony-stimulating factor (G-CSF) to enhance stem cell mobilization prior to autologous stem cell transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
Molekularmasse
502,8000 g/mol
LogP
0,00
TPSA
78,70 Ų
Lipinski-Regel der Fünf
Nicht bestanden
Therapeutische Bereiche
Wirkmechanismus
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D-Struktur
Cite this structure
Embed this structure
SMILES
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1
InChI
InChI=1S/C28H54N8/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36/h5-8,29-34H,1-4,9-26H2
Molecular Formula
C28H54N8
HBD / HBA
6 / 8
Rotierbare Bindungen
4
Schwere Atome
36
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Plerixafor is a bicyclam CXCR4 chemokine receptor antagonist that blocks the interaction between CXCR4 and its ligand CXCL12/SDF-1, thereby mobilizing hematopoietic stem and progenitor cells from the bone marrow into the peripheral blood. It is used in combination with granulocyte colony-stimulating factor (G-CSF) to enhance stem cell mobilization prior to autologous stem cell transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Plerixafor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL18442. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 65015. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="plerixafor"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/plerixafor/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/plerixafor/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/plerixafor/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="plerixafor"></drugfyi-drug>